P0F Stock Chart & Stats
$0.80
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$0.36 - $0.92
Previous CloseN/A
VolumeN/A
Average Volume (3M)103.00
Market Cap
€386.88M
Enterprise Value$2.34B
Total Cash (Recent Filing)€378.40M
Total Debt (Recent Filing)€68.80M
Price to Earnings (P/E)―
Beta-0.66
Next Earnings
Nov 06, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding464,965,580
10 Day Avg. Volume0
30 Day Avg. Volume103
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)5.81
Price to Sales (P/S)31.51
P/FCF Ratio-7.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.97Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.06
Revenue Forecast (FY)€59.87M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe strong increase in trailing revenue indicates improving commercial progress and product uptake from a still-small base. If sustained, this growth can improve operating leverage, support broader commercialization, and gradually reduce the gap between the company’s revenue base and its substantial development costs.
Rare-Disease FocusA focused rare-disease strategy can support differentiated products and concentrated expertise in markets where treatment options are limited. Late-stage development and commercialization of therapies for serious unmet needs may provide a durable basis for adoption and specialized competitive positioning.
Moderate LeverageModerate leverage and a sizable equity base provide more balance-sheet support than a highly debt-funded structure. This reduces immediate debt-related pressure and preserves some financial flexibility while the company works to advance its pipeline and improve commercial performance.
Bears Say
Persistent Cash BurnLarge negative operating and free cash flow show that the business is not yet self-funding and remains dependent on external financing or other capital sources. Continued cash burn can constrain investment choices and create funding pressure if revenue growth does not materially improve.
Deep Operating LossesThe scale of operating and net losses shows that costs remain far above the current revenue base, limiting operating leverage and earnings visibility. Even with improved sales, the company remains materially distant from sustainable profitability, leaving performance highly dependent on future commercialization gains.
Profitability-Driven Equity RiskDeeply negative returns on equity indicate that the current asset and capital base is not generating adequate economic returns. If losses persist, accumulated deficits can erode equity and reduce financial resilience, making improved profitability increasingly important for long-term stability.
Egetis Therapeutics AB News
P0F FAQ
What was Egetis Therapeutics AB’s price range in the past 12 months?
Egetis Therapeutics AB lowest stock price was $0.36 and its highest was $0.92 in the past 12 months.
What is Egetis Therapeutics AB’s market cap?
Egetis Therapeutics AB’s market cap is €386.88M.
When is Egetis Therapeutics AB’s upcoming earnings report date?
Egetis Therapeutics AB’s upcoming earnings report date is Nov 06, 2026 which is in 9 days.
How were Egetis Therapeutics AB’s earnings last quarter?
Egetis Therapeutics AB released its earnings results on Aug 21, 2026. The company reported -$0.022 earnings per share for the quarter, missing the consensus estimate of -$0.014 by -$0.009.
Is Egetis Therapeutics AB overvalued?
According to Wall Street analysts Egetis Therapeutics AB’s price is currently Undervalued.
Does Egetis Therapeutics AB pay dividends?
Egetis Therapeutics AB does not currently pay dividends.
What is Egetis Therapeutics AB’s EPS estimate?
Egetis Therapeutics AB’s EPS estimate is -0.02.
How many shares outstanding does Egetis Therapeutics AB have?
Egetis Therapeutics AB has 464,965,580 shares outstanding.
What happened to Egetis Therapeutics AB’s price movement after its last earnings report?
Egetis Therapeutics AB reported an EPS of -$0.022 in its last earnings report, missing expectations of -$0.014. Following the earnings report the stock price went down -2.504%.
Which hedge fund is a major shareholder of Egetis Therapeutics AB?
Currently, no hedge funds are holding shares in DE:P0F
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Egetis Therapeutics AB
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
P0F Stock 12 Month Forecast
Average Price Target
$2.97